Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | ADA | P00813 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | GAPDH | P04406 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8173011 | 0.92 | ADORA1 (0.56) | ADORA1ADAPOLBADORA3DPP4 | |
| SCHEMBL29403419 | 0.92 | ADORA1 (0.56) | ADORA1ADAPOLBADORA3DPP4 | |
| SCHEMBL13528511 | 0.89 | ADORA1 (0.64) | ADORA1ADAPOLBSMN1; SMN2ENPP1 | |
| SCHEMBL29547295 | 0.89 | ADORA1 (0.64) | ADORA1ADAPOLBSMN1; SMN2ENPP1 | |
| SCHEMBL3502762 | 0.89 | ADORA1 (0.64) | ADORA1ADAPOLBSMN1; SMN2ENPP1 | |
| SCHEMBL8175190 | 0.85 | POLB (0.60) | ADORA1ADAPOLBENPP1P2RY1 | |
| SCHEMBL8167619 | 0.85 | POLB (0.59) | ADORA1POLBSMN1; SMN2ENPP1P2RY1 | |
| SCHEMBL8174805 | 0.85 | POLB (0.59) | ADORA1POLBSMN1; SMN2ENPP1P2RY1 | |
| SCHEMBL10446527 | 0.84 | ADA (0.58) | ADORA1ADAPOLBADORA3DPP4 | |
| SCHEMBL4580720 | 0.84 | ADA (0.58) | ADORA1ADAPOLBADORA3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022381-A1 | RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12503696-B2 | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12378558-B2 | RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250215433-A1 | RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use | Arrowhead Pharmaceuticals, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-20250075214-A1 | RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of Use | Arrowhead Pharmaceuticals, Inc. | 2025-03-06 | — | — | US | disclosed |
| WO-2025049773-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE), PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215433-A1 | RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use | CFH, CFB, F13B | ADORA1 3413/4885ADA 3331/4885POLB 816/4885 |
| US-20260022381-A1 | RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of Use | CFH, CFB, F13B | ADORA1 3022/4885ADA 2499/4885POLB 583/4885 |
| US-12378558-B2 | RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use | CFH, CFB, C1R | ADORA1 3176/4885ADA 3580/4885POLB 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.